Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carbidopa + levodopa + entacapone
- Development stage
- Unknown
- Lead developer
- Orion Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Carbidopa + levodopa + entacapone is a fixed-dose combination oral medication used to treat Parkinson's disease. It combines three active ingredients with complementary mechanisms of action. Levodopa is converted into dopamine in the brain, helping to alleviate motor symptoms caused by dopamine deficiency in Parkinson’s disease. Carbidopa inhibits dopa decarboxylase, preventing the peripheral breakdown of levodopa and increasing its availability to the brain. Entacapone inhibits catechol-O-methyltransferase (COMT), further reducing peripheral metabolism of levodopa and prolonging its effect. The combination improves symptom control and reduces "wearing-off" effects compared to levodopa/carbidopa alone[1][3][8]. Developed for convenience, it reduces pill burden for patients requiring all three agents.
- Brand names
- StalevoLevodopa/Carbidopa/Entacapone Orion
02
Targets
COMT (Catechol-O-methyltransferase)DDC (Aromatic L-amino acid decarboxylase)
Beyond the preview
Go deeper on carbidopa + levodopa + entacapone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carbidopa + levodopa + entacapone.